Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2026
Reporting Period: Event-based (January 9, 2026)
Business Context: The Company is a biopharmaceutical entity focused on gene therapy, listed on The Nasdaq Global Select Market under the symbol "QURE". This filing serves as a Regulation FD disclosure regarding a scheduled regulatory meeting.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
There are no material changes to financial performance or operations reported in this document. The sole material event is the scheduling of a Type A meeting with the U.S. Food and Drug Administration (FDA).
Guidance, Outlook, and Management Commentary
- Regulatory Update: On January 9, 2026, uniQure N.V. announced that a Type A meeting with the FDA has been scheduled.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) by reference but does not include specific management commentary, forward-looking guidance, or risk factors within the body of the 8-K text itself.
- Unusual Items: None reported.
Investor Verification Checklist
- Verify the specific agenda and date of the scheduled Type A FDA meeting by reviewing the press release attached as Exhibit 99.1.
- Confirm the therapeutic area or specific drug candidate associated with the FDA meeting.
- Review subsequent filings for the outcome of the FDA meeting and any impact on the Company's development timeline.
- Check the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not provide financial data.